Benzonatate Modified Release Tablets Preventing Buccal Numbness
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Benzonatate, a non-narcotic oral cough suppressant, experiences undesirable side effects such as rapid development of numbness in the mouth and throat when not swallowed intact, leading to potential pulmonary aspiration due to excessive absorption in the oral mucosa, and existing formulations lack a modified release profile to prevent buccal cavity release.
Innovation Solution
A modified release benzonatate solid composition is developed, comprising benzonatate adsorbed onto porous silicon dioxide with a water-soluble polyethylene oxide resin, and a bucco-protective coating to prevent premature release in the buccal cavity, providing an extended release profile of 8 to 12 hours and resistance to dose-dumping in the presence of alcoholic beverages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If benzonatate is formulated as immediate release composition, then therapeutic effect is achieved quickly, but side effects occur due to rapid absorption in oral mucosa when not swallowed intact
Solution Approach 1:
The patent applies preliminary action by pre-coating the benzonatate composition with a protective coating before administration. This coating is designed to prevent premature release and absorption in the buccal cavity, thereby preventing numbness and aspiration risks before they can occur. The coating acts as a preventive measure that ensures the drug is only released after swallowing, maintaining safety while preserving therapeutic efficacy.
Solution Approach 2:
The protective coating serves as an intermediary between the benzonatate active ingredient and the buccal mucosa. This intermediate layer prevents direct contact and absorption of the drug in the mouth, eliminating the harmful effects of rapid local absorption while allowing controlled release in the gastrointestinal tract where therapeutic absorption occurs.
2Object-affected harmful factors
If benzonatate is swallowed intact for safety, then buccal absorption is avoided, but patient compliance decreases due to difficulty in swallowing and risk of choking
Solution Approach 1:
The patent applies local quality by creating a composition with differentiated properties in different locations: the protective coating provides a smooth, easy-to-swallow exterior that reduces choking risk and improves compliance, while the interior contains the benzonatate active ingredient that releases only after gastrointestinal dissolution. This spatial differentiation of properties allows both safety and ease of administration.
Solution Approach 2:
The invention uses composite materials by combining benzonatate with a protective coating material and matrix-forming substances. This composite structure provides both the therapeutic function of benzonatate and the safety/functionality of the coating system, creating a multi-functional dosage form that is both safe and easy to administer.
3Object-affected harmful factors
If coating is applied to prevent buccal release, then safety is improved, but manufacturing complexity increases
Solution Approach 1:
The patent merges the coating function and matrix formulation into an integrated system. The protective coating is combined with matrix-forming substances that provide both structural integrity and controlled release functionality. This merging reduces the number of separate manufacturing steps and simplifies the overall process while maintaining the safety benefits of preventing buccal release.
Solution Approach 2:
The coating and matrix system serves multiple functions simultaneously: it provides protective coating to prevent buccal absorption, creates a matrix for controlled release, and facilitates easy swallowing. This multi-functionality reduces the need for separate components and processes, thereby reducing manufacturing complexity while achieving multiple objectives.
4Loss of time
If modified release profile is implemented, then dosing frequency is reduced and convenience is improved, but formulation complexity increases
Solution Approach 1:
The patent combines the protective coating function with the modified release matrix into a single integrated formulation system. The matrix-forming substances serve dual purposes of providing structural integrity for easy swallowing and controlling the release profile over time. This merging achieves extended release and dosing convenience without requiring separate complex mechanisms.
Solution Approach 2:
The invention achieves modified release by changing the physical and chemical parameters of the formulation, specifically using matrix-forming substances with controlled porosity and degradation characteristics. By adjusting these material parameters rather than adding complex mechanical release mechanisms, the patent achieves extended release with relatively simple formulation changes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified release composition reduces the frequency of dosing, minimizes undesirable side effects by avoiding buccal cavity release, and maintains therapeutic plasma levels for an extended period, ensuring safety and convenience for patients.
Implementation Method 1
benzonatate adsorbed onto porous silicon dioxide
Implementation Method 2
a bucco-protective coating to prevent premature release in the buccal cavity
Implementation Method 3
water-soluble polyethylene oxide resin in an amount effective to provide a modified release profile
Data Source
AI summary
A 12-hour anti-tussive modified release solid tablet or tablet-in-capsule is described which comprises a benzonatate-silicon dioxide adsorbate powder in a hydrophilic matrix to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 1% release of the benzonatate within half an hour as determined in an in vitro dissolution assay.